Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Windows 11 feeling bloated? Sophia Script lets you reshape the OS from the inside out. Here's how it works.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Unwind by hunting for words on the day’s themed list — they’re hidden horizontally, vertically, diagonally and backward. Come back daily for a new theme or to browse the recent archive. Jump in to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results